Epigenomics launches next-gen colon cancer blood test in Europe
This article was originally published in Clinica
Executive Summary
Epigenomics is launching a new version of its colorectal cancer blood test, called Epi proColon 2.0 CE, in Europe. The diagnostic has shown sensitivity of 80% and specificity of 99%; by comparison, the first-generation test demonstrated sensitivity and specificity of 67% and 88%.